Welcome to our dedicated page for Therapeuticsmd news (Ticker: TXMD), a resource for investors and traders seeking the latest updates and insights on Therapeuticsmd stock.
TherapeuticsMD, Inc. reports recurring updates about its pharmaceutical royalty business, which owns rights to royalties from licensed pharmaceutical products and no longer conducts research and development or commercial operations. The company’s news is centered on license revenue, primarily under the Mayne License Agreement, changes in sales of licensed products, operating expense levels after its transition to a royalty-based model, and results from continuing operations.
TherapeuticsMD also provides corporate strategy updates, including disclosures about its ongoing evaluation of strategic alternatives. Its historical context includes a December 2022 shift from a women’s healthcare commercialization business to a company focused on collecting royalties from licensees.
TherapeuticsMD, Inc. (NASDAQ: TXMD) has appointed Mark Glickman as its new Chief Business Officer. Glickman, who has extensive experience in commercial roles at various pharmaceutical companies, will receive 660,000 restricted stock units (RSUs) and 260,000 performance stock units (PSUs) as part of his inducement package. The RSUs will vest over three years, while the PSUs are tied to revenue performance metrics. The appointment is part of the company's strategy to strengthen its leadership in women's healthcare.
Theramex has launched Bijuva® / Bijuve® (1mg estradiol / 100mg progesterone) in Europe and the UK. This body-identical hormone therapy is the first of its kind for post-menopausal women with intact uterus, aimed at alleviating symptoms of estrogen deficiency. Unlike synthetic hormones, Bijuva® and Bijuve® are chemically identical to natural hormones, associated with lower health risks. Clinical trials show significant improvements in vasomotor symptoms and quality of life during treatment, making it a vital option for women seeking effective HRT.
TherapeuticsMD, Inc. (NASDAQ: TXMD) is recognizing Menopause Awareness Month to empower the 64 million U.S. women currently in menopause. With over 80% experiencing symptoms, the company highlights vulvar and vaginal atrophy (VVA), affecting more than half of menopausal women. The 'Take Pause' initiative includes educational videos featuring Dr. Rebecca Brightman to raise awareness about VVA and available treatments such as IMVEXXY. This effort aims to normalize discussions around menopause and its symptoms, encouraging women to seek care.
TherapeuticsMD (NASDAQ: TXMD) announced that CMS confirmed a permanent product-specific HCPCS J Code for ANNOVERA, effective October 1, 2021. This new coding will enable Title X Family Planning clinics to gain reimbursement for dispensing ANNOVERA, streamlining billing processes for approximately 4,900 facilities. The J Code is unique to ANNOVERA, enhancing patient access to the only yearly, patient-controlled vaginal contraceptive in the market. This development reflects a push towards improving women's healthcare accessibility.
TherapeuticsMD, Inc. (NASDAQ: TXMD) announced the appointment of Hugh O’Dowd as President, succeeding John C.K. Milligan, IV, now CEO of vitaCare Prescription Services. O’Dowd brings over 20 years of experience, notably at Novartis, and aims to enhance the company's value and commercialization efforts in women's health. The company also plans to grant O’Dowd 2.75 million RSUs and PSUs as part of his inducement. The management change reflects a strategic move to strengthen leadership in advancing TherapeuticsMD's portfolio.
TherapeuticsMD (TXMD) reported second-quarter 2021 financial results, highlighting a strong growth in net product revenues amounting to $23 million, up from $10.7 million in Q2 2020. Key products ANNOVERA and IMVEXXY saw substantial revenue increases of 202% and 56%, respectively. The company also noted progress in prescription growth and access to telemedicine. Despite a net loss of $42.7 million, up from $39.4 million in Q1 2021, cash on hand rose to $111.4 million. The firm is exploring investment opportunities in vitaCare, aiming for non-dilutive capital options.
TherapeuticsMD, a leader in women's healthcare, is set to announce its Q2 2021 financial results on August 4, 2021, before U.S. markets open. The executive team will host a conference call at 8:30 a.m. ET for a financial review and business update. Interested parties can access the call via U.S. and international lines or through a live webcast at therapeuticsmd.com. The event will also be archived for 30 days for replay. TherapeuticsMD is focused on advancing women's health through innovative products.
TherapeuticsMD, Inc. (NASDAQ: TXMD) announced the submission of a supplemental New Drug Application (sNDA) for low-dose BIJUVA (estradiol and progesterone) capsules to the FDA. The company anticipates receiving acceptance notification within approximately 74 days, with a potential review period of ten months. BIJUVA is already approved for moderate to severe vasomotor symptoms due to menopause. The CEO expressed optimism about the new dosage providing additional therapeutic options for women.
Summary not available.
TherapeuticsMD, Inc. (NASDAQ: TXMD) reported a 60% increase in net product revenue for Q1 2021, totaling $19.6 million, compared to Q1 2020. The performance was driven by strong sales of ANNOVERA, which saw revenues rise to $8.8 million, and BIJUVA, which grew by 120% to $2.5 million. The company also secured three new patents for ANNOVERA, extending exclusivity to June 2039. Despite a 13% decline in revenue from Q4 2020, the overall outlook remains positive with a continuous improvement in financial performance.